Evidence map›Paper›PMID 31188952›Full record

ArticleMemorias do Instituto Oswaldo Cruz2019

A new heparan sulfate from the mollusk Nodipecten nodosus inhibits merozoite invasion and disrupts rosetting and cytoadherence of Plasmodium falciparum.

Marcele F Bastos, Letusa Albrecht, Angélica M Gomes, Stefanie Cp Lopes, Cristina P Vicente, Rodrigo Pm de Almeida, Gustavo C Cassiano, Roberto Jc Fonseca, Claudio C Werneck, Mauro Sg Pavão and 1 more

Open access · diamondAbstract readEvaluation Study
In one paragraph

Article in Memorias do Instituto Oswaldo Cruz, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Unveiling the Sugary Secrets ofFrontiers in microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Marcele F BastosUniversidade Estadual de Campinas, Departamento de Genética, Evolução, Microbiologia e Imunologia, Laboratório de Doenças Tropicais, Campinas, SP, Brasil.
Letusa AlbrechtFundação Oswaldo Cruz-Fiocruz, Instituto Carlos Chagas, Curitiba, PR, Brasil.
Angélica M GomesCleveland Clinic Lerner Research Institute, Department of Biomedical Engineering, Cleveland, OH, USA.
Stefanie Cp LopesFundação Oswaldo Cruz-Fiocruz, Instituto Leônidas e Maria Deane, Manaus, AM, Brasil.
Cristina P VicenteUniversidade Estadual de Campinas, Departamento de Biologia Estrutural e Funcional, Campinas, SP, Brasil.
Rodrigo Pm de AlmeidaFundação Oswaldo Cruz-Fiocruz, Instituto Carlos Chagas, Curitiba, PR, Brasil.
Gustavo C CassianoUniversidade Estadual de Campinas, Departamento de Genética, Evolução, Microbiologia e Imunologia, Laboratório de Doenças Tropicais, Campinas, SP, Brasil.
Roberto Jc FonsecaUniversidade Federal do Rio de Janeiro, Centro de Ciências da Saúde, Instituto de Ciências Biomédicas, Hospital Universitário Clementino Fraga Filho, Laboratório de Tecido Conjuntivo, Rio de Janeiro, RJ, Brasil.
Claudio C WerneckUniversidade Estadual de Campinas, Departamento de Bioquímica e Biologia Tecidual, Campinas, SP, Brasil.
Mauro Sg PavãoUniversidade Federal do Rio de Janeiro, Instituto de Bioquímica Médica Leopoldo de Meis, Programa de Glicobiologia, Rio de Janeiro, RJ, Brasil.
Fabio Tm CostaUniversidade Estadual de Campinas, Departamento de Genética, Evolução, Microbiologia e Imunologia, Laboratório de Doenças Tropicais, Campinas, SP, Brasil.ORCID http://orcid.org/0000-0001-9969-7300
Universidade Estadual de Campinas (UNICAMP) · BRFundação Carlos Chagas · BRUniversidade Federal do Rio de Janeiro · BRCleveland Clinic Lerner College of Medicine · USFundação Oswaldo Cruz · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite treatment with effective antimalarial drugs, the mortality rate is still high in severe cases of the disease, highlighting the need to find adjunct therapies that can inhibit the adhesion of Plasmodium falciparum-infected erythrocytes (Pf-iEs).

objectivesIn this context, we evaluated a new heparan sulfate (HS) from Nodipecten nodosus for antimalarial activity and inhibition of P. falciparum cytoadhesion and rosetting.

methodsParasite inhibition was measured by SYBR green using a cytometer. HS was assessed in rosetting and cytoadhesion assays under static and flow conditions using Chinese hamster ovary (CHO) and human lymphatic endothelial cell (HLEC) cells expressing intercellular adhesion molecule-1 (ICAM1) and chondroitin sulfate A (CSA), respectively.

findingsThis HS inhibited merozoite invasion similar to heparin. Moreover, mollusk HS decreased cytoadherence of P. falciparum to CSA and ICAM-1 on the surface of endothelial cells under static and flow conditions. In addition, this glycan efficiently disrupted rosettes.

conclusionsThese findings support a potential use for mollusk HS as adjunct therapy for severe malaria.

Indexed as

AnimalsCell AdhesionErythrocytesHeparan SulfateMerozoitesMolluscaPlasmodium falciparumProtozoan ProteinsReproducibility of ResultsTime FactorsHeparan SulfateProtozoan Proteins

Identifiers

PMID31188952
PMCPMC6555591
OpenAlexW2949043934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.